scholarly journals Real World Data On Labor Procedures In The Brazilian Unified Health System (SUS). An Eight Years Retrospective Database Study

2017 ◽  
Vol 20 (9) ◽  
pp. A925
Author(s):  
ÉV Carmo
Keyword(s):  
Health System ◽  
Real World ◽  
Real World Data ◽  
Database Study ◽  
World Data ◽  
Unified Health System ◽  
Retrospective Database

Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia

2019 ◽  
Vol 8 (13) ◽  
pp. 1111-1123 ◽  
Author(s):  
Brooke M Faught ◽  
Graziella Soulban ◽  
Jason Yeaw ◽  
Christiane Maroun ◽  
Katharine Coyle ◽  
...  
Keyword(s):  
Real World ◽  
Healthcare Costs ◽  
Claims Data ◽  
The Other ◽  
Real World Data ◽  
Database Study ◽  
World Data ◽  
Pharmacy Claims ◽  
Direct Healthcare Costs ◽  
Retrospective Database

Aim: Objective was to compare adherence and persistence, as well as direct healthcare costs and utilization, of ospemifene to available local estrogen therapies (LETs). Patients & methods: This retrospective database study used integrated medical and pharmacy claims data from the IQVIA Real-World Data Adjudicated Claims – US Database. Results: Ospemifene patients had significantly greater adherence and persistence compared with the other nonring LETs. Ospemifene had the lowest mean outpatient costs of any of the LET cohorts, including the estradiol vaginal ring. Total all-cause healthcare costs were also significantly less for ospemifene patients compared with all other LETs.

scholarly journals Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn’s Disease using Real-World Data

2019 ◽  
Vol 14 (4) ◽  
pp. 490-500 ◽  
Author(s):  
Nadia Pillai ◽  
Judith E Lupatsch ◽  
Mark Dusheiko ◽  
Matthias Schwenkglenks ◽  
Michel Maillard ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Cost Effectiveness ◽  
Crohn's Disease ◽  
Health System ◽  
Real World ◽  
Transition Probabilities ◽  
Cost Effective ◽  
Real World Data ◽  
World Data ◽  
The Cost

Abstract Background and Aims We evaluated the cost-effectiveness of early [≤2 years after diagnosis] compared with late or no biologic initiation [starting biologics >2 years after diagnosis or no biologic use] for adults with Crohn’s disease in Switzerland. Methods We developed a Markov cohort model over the patient’s lifetime, from the health system and societal perspectives. Transition probabilities, quality of life, and costs were estimated using real-world data. Propensity score matching was used to ensure comparability between patients in the early [intervention] and late/no [comparator] biologic initiation strategies. The incremental cost-effectiveness ratio [ICER] per quality-adjusted life year [QALY] gained is reported in Swiss francs [CHF]. Sensitivity and scenario analyses were performed. Results Total costs and QALYs were higher for the intervention [CHF384 607; 16.84 QALYs] compared with the comparator [CHF340 800; 16.75 QALYs] strategy, resulting in high ICERs [health system: CHF887 450 per QALY; societal: CHF449 130 per QALY]. In probabilistic sensitivity analysis, assuming a threshold of CHF100 000 per QALY, the probability that the intervention strategy was cost-effective was 0.1 and 0.25 from the health system and societal perspectives, respectively. In addition, ICERs improved when we assumed a 30% reduction in biologic prices [health system: CHF134 502 per QALY; societal: intervention dominant]. Conclusions Early biologic use was not cost-effective, considering a threshold of CHF100 000 per QALY compared with late/no biologic use. However, early identification of patients likely to need biologics and future drug price reductions through increased availability of biosimilars may improve the cost-effectiveness of an early treatment approach.

scholarly journals PCN28 Capecitabine for the Treatment of Breast Cancer in Private Health System in Brazil: Cost analysis Based on Real World Data

2011 ◽  
Vol 14 (7) ◽  
pp. A438
Author(s):  
O. Clark ◽  
L.G.O. Clark ◽  
T.E.A. Botrel ◽  
B. Rosa ◽  
P. Medina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Analysis ◽  
Health System ◽  
Real World ◽  
Real World Data ◽  
World Data

scholarly journals PCN35 Capecitabine for the Treatment of Colorectal Cancer in Private Health System in Brazil: A Budgetary Impact Analysis Based on Real World Data

2011 ◽  
Vol 14 (7) ◽  
pp. A440
Author(s):  
O. Clark ◽  
L.G.O. Clark ◽  
T.E.A. Botrel ◽  
L. Paladini ◽  
P. Medina ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Health System ◽  
Real World ◽  
Impact Analysis ◽  
Real World Data ◽  
Budgetary Impact ◽  
World Data

scholarly journals PCN350 USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF CANADIANS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA

2020 ◽  
Vol 23 ◽  
pp. S86
Author(s):  
S.J. Seung ◽  
M. Hurry ◽  
S. Hassan ◽  
R.N. Walton ◽  
A. Elnoursi ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Health System ◽  
Real World ◽  
Lymphocytic Leukemia ◽  
Real World Data ◽  
World Data
Sign in / Sign up

Export Citation Format

Share Document